Halcinonide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 328806

CAS#: 3093-35-4

Description: Halcinonide, also known as Halog and SQ-18566, is a glucocorticoid used topically in the treatment of dermatitis, eczema, or psoriasis.


Price and Availability

Size
Price

200mg
USD 500
Size
Price

Size
Price

Halcinonide (Halog, SQ-18566), purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 328806
Name: Halcinonide
CAS#: 3093-35-4
Chemical Formula: C24H32ClFO5
Exact Mass: 454.1922
Molecular Weight: 454.9634
Elemental Analysis: C, 63.36; H, 7.09; Cl, 7.79; F, 4.18; O, 17.58


Synonym: Halcinonide; Halog; SQ-18566; SQ18566; SQ 18566;

IUPAC/Chemical Name: (6aS,6bR,7S,8aS,8bS,11aS,12aS,12bS)-8b-(2-chloroacetyl)-6b-fluoro-7-hydroxy-6a,8a,10,10-tetramethyl-1,2,5,6,6a,6b,7,8,8a,8b,11a,12,12a,12b-tetradecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one

InChi Key: MUQNGPZZQDCDFT-DGRLEXMWSA-N

InChi Code: InChI=1S/C24H32ClFO5/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,26)17(28)11-22(16,4)24(19,31-20)18(29)12-25/h9,15-17,19,28H,5-8,10-12H2,1-4H3/t15-,16-,17-,19-,21-,22-,23-,24+/m0/s1

SMILES Code: C[C@@]12[C@@]3(C(CCl)=O)[C@](OC(C)(O3)C)([H])C[C@@]1([H])[C@]4([H])CCC5=CC(CC[C@]5(C)[C@@]4(F)[C@@H](O)C2)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Draelos ZD. Demonstration of the biphasic release of 0.1% halcinonide cream. J Drugs Dermatol. 2015 Jan;14(1):89-90. PubMed PMID: 25607913.

2: Porcu G, Serone E, De Nardis V, Di Giandomenico D, Lucisano G, Scardapane M, Poma A, Ragnini-Wilson A. Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation. PLoS One. 2015 Dec 10;10(12):e0144550. doi: 10.1371/journal.pone.0144550. eCollection 2015. PubMed PMID: 26658258; PubMed Central PMCID: PMC4689554.

3: Draelos ZD. Stratum corneum absorption kinetics of 2 potent topical corticosteroid formulations: a pilot study. Cutis. 2015 Aug;96(2):135-41. PubMed PMID: 26367752.

4: Clijsen R, Baeyens JP, Barel AO, Clarys P. Influence of the timing of ultrasound application on the penetration of corticosteroids. Skin Res Technol. 2013 Feb;19(1):e279-82. doi: 10.1111/j.1600-0846.2012.00639.x. Epub 2012 Jun 20. PubMed PMID: 22712560.

5: Baum EW. Effectiveness and Patient Acceptance of Halcinonide 0.1% Cream in 216g Jars for Large-area Steroid-responsive Dermatoses. J Clin Aesthet Dermatol. 2011 Apr;4(4):29-33. PubMed PMID: 21532875; PubMed Central PMCID: PMC3084610.

6: Bickers DR. A comparative study of amcinonide and halcinonide in the treatment of eczematous dermatitis. Cutis. 1984 Aug;34(2):190-4. PubMed PMID: 6383735.

7: Shi HH, Zhu L, Yang Y, Jin HM, Li RZ, Liang ZQ, Lang JH. [Multicenter randomized clinical study of high-intensity focused ultrasound and cortical hormone in the treatment of non-neoplastic epithelial disorders of vulva]. Zhonghua Yi Xue Za Zhi. 2013 Nov 5;93(41):3291-3. Chinese. PubMed PMID: 24401626.

8: Rauschkolb EW, Bender SH, Ebling JK, McCormick GE, Rosenthal AL. Low concentration halcinonide cream in the topical management of atopic dermatitis in pediatric patients. Cutis. 1981;27(1):105-7. PubMed PMID: 7471802.

9: Zhang YD, Yao W, Wu CX, Chi QM, Zhang JY, Li M. Tropical application of halcinonide cream reduces the severity and incidence of intraperitoneal adhesions in a rat model. Am J Surg. 2002 Jul;184(1):74-77. PubMed PMID: 12152622.

10: Guenther L, Solomon AR, Voorhees JJ. A controlled comparison of amcinonide cream 0.1 percent and halcinonide cream 0.1 percent in the treatment of eczematous dermatitis. Cutis. 1981 Oct;28(4):461-2, 464, 467. PubMed PMID: 7030645.